Antibody Discovery Services Market by Type (Target Identification, Antibody Engineering (Technology (Hybridoma, Phage Display, Single Cell)), Immunization), Host (Mouse, Rat, Rabbit, Chicken, Camelids), Molecule (Monoclonal) - Global Forecast to 2030

1 INTRODUCTION 35 1.1 STUDY OBJECTIVES 35 1.2 MARKET DEFINITION 35 1.3 STUDY SCOPE 36 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 36 1.3.2 INCLUSIONS & EXCLUSIONS 37 1.4 YEARS CONSIDERED 37 1.4.1 CURRENCY CONSIDERED 38 1.5 STAKEHOLDERS 38 2 RESEARCH METHODOLOGY 39 2.1 RESEARCH DATA 39 2.1.1 SECONDARY DATA 40 2.1.1.1 Key secondary data sources 40 2.1.1.2 Key objectives of secondary research 40 2.1.2 PRIMARY DATA 41 2.1.2.1 Breakdown of primaries 41 2.1.2.2 Key objectives of primary research 42 2.2 MARKET ESTIMATION METHODOLOGY 42 2.2.1 MARKET ESTIMATION 43 2.2.1.1 Company revenue analysis (bottom-up approach) 43 2.2.1.2 MnM repository analysis & primary interviews 44 2.2.1.3 Insights from primary experts 45 2.2.1.4 Segmental market size estimation by top-down approach 45 2.3 MARKET GROWTH RATE PROJECTIONS 46 2.4 DATA TRIANGULATION 49 2.5 STUDY ASSUMPTIONS 50 2.6 RESEARCH LIMITATIONS 50 2.7 RISK ANALYSIS 51 3 EXECUTIVE SUMMARY 52 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS 52 3.2 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS 57 3.3 DISRUPTIVE TRENDS SHAPING ANTIBODY DISCOVERY SERVICES MARKET 57 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 58 3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 60   4 PREMIUM INSIGHTS 61 4.1 ANTIBODY DISCOVERY SERVICES MARKET OVERVIEW 61 4.2 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE AND COUNTRY (2024) 62 4.3 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2025 VS. 2030 63 4.4 ANTIBODY DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63 4.5 ANTIBODY DISCOVERY SERVICES MARKET SHARE, BY TYPE 64 4.6 UNMET NEEDS & WHITE SPACES 64 4.7 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 65 4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 66 4.9 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 67 4.10 VC/PRIVATE EQUITY INVESTMENT TRENDS 68 4.11 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 69 4.11.1 SUSTAINABILITY IMPACT 69 4.11.2 REGULATORY POLICIES & ACCESS INITIATIVES 69 4.12 IP/PATENT LANDSCAPE IN ANTIBODY DISCOVERY SERVICES MARKET 69 5 MARKET OVERVIEW 71 5.1 INTRODUCTION 71 5.2 MARKET DYNAMICS 71 5.2.1 DRIVERS 72 5.2.1.1 Development of bispecific antibodies and antibody fragments 72 5.2.1.2 Rising number of antibody-drug conjugates in clinical trials 73 5.2.1.3 Increasing venture and partnership funding for biologics 73 5.2.2 RESTRAINTS 74 5.2.2.1 High costs and complexity of biologics discovery 74 5.2.2.2 Competition from alternative modalities 74 5.2.2.3 Patent cliffs for blockbuster monoclonal antibodies and rise of biosimilars 74 5.2.3 OPPORTUNITIES 75 5.2.3.1 End-to-end discovery–to–IND service bundles/one-stop shop models in antibody discovery 75 5.2.3.2 Integration of AI and automation in discovery workflow 75 5.2.4 CHALLENGES 76 5.2.4.1 Reagents and raw material supply chain bottlenecks 76 5.2.4.2 Fragmented data and disjointed workflow infrastructure 76   6 INDUSTRY TRENDS 77 6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 77 6.2 VALUE CHAIN ANALYSIS 78 6.3 ECOSYSTEM ANALYSIS 79 6.3.1 RAW MATERIAL SUPPLIERS 79 6.3.2 ANTIBODY DISCOVERY SERVICE PROVIDERS 80 6.3.3 END USERS 80 6.3.4 REGULATORY BODIES 81 6.4 INVESTMENT & FUNDING SCENARIO 82 6.4.1 MAJOR INVESTMENTS AND FUNDING 82 6.5 TECHNOLOGY ANALYSIS 83 6.5.1 KEY TECHNOLOGIES 83 6.5.1.1 Phage display platforms 83 6.5.1.2 Hybridoma technology 83 6.5.1.3 Single B-cell screening 84 6.5.2 COMPLEMENTARY TECHNOLOGIES 84 6.5.2.1 AI/ML-based protein structure prediction 84 6.5.2.2 Surface plasmon resonance (SPR)/Bio-layer interferometry (BLI) 84 6.5.2.3 Cryo-electron microscopy (CRYO-EM) 85 6.5.3 ADJACENT TECHNOLOGIES 85 6.5.3.1 CRISPR-based functional genomics 85 6.5.3.2 CHO cell line development 85 6.5.3.3 In-vivo modelling 86 6.6 PATENT ANALYSIS 86 6.6.1 METHODOLOGY 86 6.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014−2024 86 6.6.3 LIST OF KEY PATENTS 88 6.7 KEY CONFERENCES & EVENTS, 2025–2026 89 6.8 CASE STUDY ANALYSIS 90 6.8.1 BISPECIFIC ANTIBODY MANUFACTURABILITY ASSESSMENT AND OPTIMIZATION 90 6.8.2 ACCELERATING ANTIBODY DISCOVERY FOR PANDEMIC PREPAREDNESS 90 6.8.3 USE OF REPAB POLYCLONAL ANTIBODY SEQUENCING PLATFORM TO TO IDENTIFY PROTECTIVE ANTIBODIES FROM HUMAN HOSTS IMMUNE TO MALARIA 90 6.9 REGULATORY ANALYSIS 91 6.9.1 REGULATORY LANDSCAPE 91 6.9.1.1 North America 91 6.9.1.2 Europe 91 6.9.1.3 Asia Pacific 91 6.9.1.4 Rest of the World 91 6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 6.10 PORTER’S FIVE FORCES ANALYSIS 94 6.10.1 BARGAINING POWER OF SUPPLIERS 95 6.10.2 BARGAINING POWER OF BUYERS 95 6.10.3 THREAT OF NEW ENTRANTS 96 6.10.4 THREAT OF SUBSTITUTES 96 6.10.5 INTENSITY OF COMPETITIVE RIVALRY 96 6.11 KEY STAKEHOLDERS & BUYING CRITERIA 97 6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 97 6.11.2 KEY BUYING CRITERIA 98 6.12 IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET 99 6.12.1 INTRODUCTION 99 6.12.2 MARKET POTENTIAL OF AI 99 7 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE 101 7.1 INTRODUCTION 102 7.2 TARGET IDENTIFICATION & VALIDATION 102 7.2.1 INTEGRATION OF OMICS-DRIVEN INSIGHTS WITH HIGH-THROUGHPUT FUNCTIONAL VALIDATION TO PROPEL MARKET GROWTH 102 7.3 ANTIBODY ENGINEERING & OPTIMIZATION 106 7.3.1 ANTIBODY ENGINEERING & OPTIMIZATION, BY TECHNOLOGY 110 7.3.1.1 Phage display technology 110 7.3.1.1.1 Adoption of AI-enhanced phage display to augment segment growth 110 7.3.1.2 Hybridoma technology 114 7.3.1.2.1 Advancements in automation and single-cell integration to support segment growth 114 7.3.1.3 Single-cell technologies 117 7.3.1.3.1 Use of high-throughput, single-cell platforms to boost segment growth 117 7.3.1.4 Other antibody engineering & optimization technologies 121 7.4 ANTIGEN DESIGN & PRODUCTION 125 7.4.1 HIGH-QUALITY ANTIGEN DESIGN AND PRODUCTION TO SPUR SEGMENT GROWTH 125 7.5 IMMUNIZATION & HOST MANAGEMENT 129 7.5.1 RISING ADOPTION OF ADVANCED TRANSGENIC AND HUMANIZED MODELS TO PROPEL SEGMENT GROWTH 129 7.6 OTHER ANTIBODY DISCOVERY SERVICES 132 8 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST 136 8.1 INTRODUCTION 137 8.2 MOUSE & RAT 137 8.2.1 GROWING PRECLINICAL RESEARCH DEMAND TO DRIVE GROWTH 137   8.3 RABBIT 141 8.3.1 INCREASED RESEARCH AND DIAGNOSTIC APPLICATIONS TO FAVOR MARKET GROWTH 141 8.4 CHICKEN 144 8.4.1 INCREASING FOCUS OF THERAPEUTIC AND DIAGNOSTIC APPLICATIONS TO DRIVE MARKET 144 8.5 CAMELIDS 148 8.5.1 RISING ADOPTION OF NANOBODIES IN THERAPEUTICS AND DIAGNOSTICS TO BOOST MARKET GROWTH 148 8.6 OTHER HOSTS 151 9 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE 155 9.1 INTRODUCTION 156 9.2 MONOCLONAL ANTIBODIES 156 9.2.1 GROWING ADOPTION IN TISSUE TYPING FOR ORGAN & BLOOD TRANSPLANTS AND PERSONALIZED MEDICINES TO DRIVE MARKET 156 9.3 POLYCLONAL ANTIBODIES 160 9.3.1 DIVERSE EPITOPE RECOGNITION ABILITY OF POLYCLONAL ANTIBODIES TO SUPPORT SEGMENT GROWTH 160 9.4 OTHER MOLECULES 163 10 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER 167 10.1 INTRODUCTION 168 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 168 10.2.1 STRATEGIC COLLABORATIONS AND AI INTEGRATION TO BOLSTER GROWTH 168 10.3 ACADEMIC & RESEARCH INSTITUTES 172 10.3.1 INCREASING COLLABORATIVE RESEARCH AND RISING GRANT FUNDING TO AUGMENT MARKET GROWTH 172 10.4 OTHER END USERS 175 11 ANTIBODY DISCOVERY SERVICES MARKET, BY REGION 179 11.1 INTRODUCTION 180 11.2 NORTH AMERICA 181 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 184 11.2.2 US 185 11.2.2.1 US to dominate antibody discovery services market during forecast period 185 11.2.3 CANADA 188 11.2.3.1 Innovative biotech community and strategic platform investments to propel market growth 188 11.3 EUROPE 191 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 194 11.3.2 GERMANY 195 11.3.2.1 Transformative cross-border acquisitions and platform-driven antibody innovation to expedite market growth 195 11.3.3 UK 198 11.3.3.1 Ramped ADC innovation and surging biotech investment to propel market growth 198 11.3.4 FRANCE 201 11.3.4.1 Strategic biomanufacturing investments and AI-enabled innovation to support market expansion 201 11.3.5 ITALY 204 11.3.5.1 Advanced R&D infrastructure and biotech innovation to aid market growth 204 11.3.6 SPAIN 207 11.3.6.1 High biotech investment and innovation in advanced antibody modalities to drive market 207 11.3.7 REST OF EUROPE 210 11.4 ASIA PACIFIC 213 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 216 11.4.2 CHINA 217 11.4.2.1 Scalable integrated platforms, strategic global certification, and domestic innovation acceleration to augment market growth 217 11.4.3 JAPAN 220 11.4.3.1 Enhanced translational platforms and strategic cross-border R&D partnerships to expedite market growth 220 11.4.4 INDIA 223 11.4.4.1 Advanced biomanufacturing platforms and innovation-led public-private partnerships to strengthen Indian market 223 11.4.5 SOUTH KOREA 226 11.4.5.1 AI platform investments and CDMO-led modality innovation to accelerate market growth 226 11.4.6 AUSTRALIA 229 11.4.6.1 High-throughput single-cell platforms and increased academic-industry collaborations to spur market growth 229 11.4.7 REST OF ASIA PACIFIC 232 11.5 LATIN AMERICA 235 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 238 11.5.2 BRAZIL 239 11.5.2.1 Local biologics infrastructure expansion and collaborative innovation ecosystems to favor market growth 239 11.5.3 MEXICO 241 11.5.3.1 Focus on local emerging startups and industry-academic collaborations to aid antibody discovery services 241 11.5.4 REST OF LATIN AMERICA 244 11.6 MIDDLE EAST 247 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 250 11.6.2 GCC COUNTRIES 251 11.6.2.1 UAE 253 11.6.2.1.1 High biomanufacturing investments and focus on global pharmaceutical partnerships to fuel market growth 253 11.6.2.2 Kingdom of Saudi Arabia 256 11.6.2.2.1 Advanced biologics infrastructure and strategic life science innovation hubs to bolster market growth 256 11.6.2.3 Rest of GCC Countries 259 11.6.3 REST OF MIDDLE EAST 262 11.7 AFRICA 265 11.7.1 ADVANCED REGIONAL MANUFACTURING CAPABILITIES AND BIOTECH INNOVATION ECOSYSTEMS TO DRIVE MARKET 265 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 268 12 COMPETITIVE LANDSCAPE 269 12.1 INTRODUCTION 269 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 269 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET 269 12.3 REVENUE ANALYSIS, 2020–2024 271 12.4 MARKET SHARE ANALYSIS, 2024 273 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 275 12.5.1 STARS 275 12.5.2 EMERGING LEADERS 275 12.5.3 PERVASIVE PLAYERS 275 12.5.4 PARTICIPANTS 275 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 277 12.5.5.1 Company footprint 277 12.5.5.2 Region footprint 278 12.5.5.3 Type footprint 279 12.5.5.4 Host footprint 280 12.5.5.5 Molecule footprint 281 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 282 12.6.1 PROGRESSIVE COMPANIES 282 12.6.2 RESPONSIVE COMPANIES 282 12.6.3 DYNAMIC COMPANIES 282 12.6.4 STARTING BLOCKS 282 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 284 12.6.5.1 List of key startups/SMEs 284 12.6.5.2 Competitive benchmarking of key startups/SMEs 285 12.7 COMPANY VALUATION & FINANCIAL METRICS 286 12.7.1 FINANCIAL METRICS 286 12.7.2 COMPANY VALUATION 286 12.8 BRAND/SERVICE COMPARISON 287 12.9 COMPETITIVE SCENARIO 288 12.9.1 SERVICE LAUNCHES 288 12.9.2 DEALS 288 12.9.3 EXPANSIONS 289 13 COMPANY PROFILES 291 13.1 KEY PLAYERS 291 13.1.1 WUXI BIOLOGICS 291 13.1.1.1 Business overview 291 13.1.1.2 Services offered 292 13.1.1.3 Recent developments 293 13.1.1.3.1 Deals 293 13.1.1.3.2 Expansions 294 13.1.1.4 MnM view 294 13.1.1.4.1 Right to win 294 13.1.1.4.2 Strategic choices 294 13.1.1.4.3 Weaknesses & competitive threats 294 13.1.2 THERMO FISHER SCIENTIFIC INC. 295 13.1.2.1 Business overview 295 13.1.2.2 Services offered 296 13.1.2.3 Recent developments 297 13.1.2.3.1 Deals 297 13.1.2.3.2 Expansions 298 13.1.2.4 MnM view 299 13.1.2.4.1 Right to win 299 13.1.2.4.2 Strategic choices 299 13.1.2.4.3 Weaknesses & competitive threats 299 13.1.3 CHARLES RIVER LABORATORIES 300 13.1.3.1 Business overview 300 13.1.3.2 Services offered 301 13.1.3.3 Recent developments 302 13.1.3.3.1 Deals 302 13.1.3.4 MnM view 303 13.1.3.4.1 Right to win 303 13.1.3.4.2 Strategic choices 303 13.1.3.4.3 Weaknesses & competitive threats 303 13.1.4 EVOTEC 304 13.1.4.1 Business overview 304 13.1.4.2 Services offered 305 13.1.4.3 Recent developments 306 13.1.4.3.1 Deals 306 13.1.4.3.2 Contracts 307 13.1.4.3.3 Expansions 307 13.1.4.3.4 Other developments 308   13.1.4.4 MnM view 308 13.1.4.4.1 Right to win 308 13.1.4.4.2 Strategic choices 308 13.1.4.4.3 Weaknesses & competitive threats 308 13.1.5 BIOCYTOGEN 309 13.1.5.1 Business overview 309 13.1.5.2 Services offered 310 13.1.5.3 Recent developments 311 13.1.5.3.1 Service launches 311 13.1.5.3.2 Deals 311 13.1.5.3.3 Expansions 313 13.1.5.4 MnM view 313 13.1.5.4.1 Right to win 313 13.1.5.4.2 Strategic choices 313 13.1.5.4.3 Weaknesses & competitive threats 314 13.1.6 EUROFINS SCIENTIFIC 315 13.1.6.1 Business overview 315 13.1.6.2 Services offered 316 13.1.6.3 Recent developments 317 13.1.6.3.1 Expansions 317 13.1.7 SHANGHAI CHEMPARTNER 318 13.1.7.1 Business overview 318 13.1.7.2 Services offered 318 13.1.7.3 Recent developments 319 13.1.7.3.1 Deals 319 13.1.8 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES) 320 13.1.8.1 Business overview 320 13.1.8.2 Services offered 322 13.1.8.3 Recent developments 323 13.1.8.3.1 Expansions 323 13.1.9 SINO BIOLOGICAL, INC. 324 13.1.9.1 Business overview 324 13.1.9.2 Services offered 325 13.1.9.3 Recent developments 326 13.1.9.3.1 Deals 326 13.1.9.3.2 Expansions 327 13.1.10 SAMSUNG BIOLOGICS 328 13.1.10.1 Business overview 328 13.1.10.2 Services offered 329 13.1.10.3 Recent developments 330 13.1.10.3.1 Service launches 330   13.1.11 GENSCRIPT 331 13.1.11.1 Business overview 331 13.1.11.2 Services offered 332 13.1.11.3 Recent developments 333 13.1.11.3.1 Service launches 333 13.1.11.3.2 Deals 334 13.1.12 CURIA GLOBAL, INC. 335 13.1.12.1 Business overview 335 13.1.12.2 Services offered 335 13.1.12.3 Recent developments 336 13.1.12.3.1 Deals 336 13.1.12.3.2 Other developments 337 13.1.13 TWIST BIOSCIENCE 338 13.1.13.1 Business overview 338 13.1.13.2 Services offered 339 13.1.13.3 Recent developments 341 13.1.13.3.1 Service launches 341 13.1.13.3.2 Deals 341 13.1.13.3.3 Expansions 341 13.1.14 HARBOUR BIOMED 342 13.1.14.1 Business overview 342 13.1.14.2 Services offered 343 13.1.14.3 Recent developments 343 13.1.14.3.1 Deals 343 13.1.14.3.2 Other developments 345 13.1.15 ARAGEN LIFE SCIENCES LTD. 346 13.1.15.1 Business overview 346 13.1.15.2 Services offered 347 13.1.15.3 Recent developments 347 13.1.15.3.1 Expansions 347 13.1.16 DANAHER CORPORATION 348 13.1.16.1 Business overview 348 13.1.16.2 Services offered 349 13.1.16.3 Recent developments 350 13.1.16.3.1 Deals 350 13.1.17 CREATIVE BIOLABS 351 13.1.17.1 Business overview 351 13.1.17.2 Services offered 351 13.1.18 VIVA BIOTECH 353 13.1.18.1 Business overview 353 13.1.18.2 Services offered 355   13.1.19 IMMUNOPRECISE ANTIBODIES LTD. 356 13.1.19.1 Business overview 356 13.1.19.2 Services offered 357 13.1.19.3 Recent developments 359 13.1.19.3.1 Deals 359 13.1.20 FUSION ANTIBODIES 360 13.1.20.1 Business overview 360 13.1.20.2 Services offered 361 13.2 OTHER PLAYERS 363 13.2.1 ABZENA 363 13.2.2 ALLOY THERAPEUTICS, INC. 364 13.2.3 INTEGRAL MOLECULAR 365 13.2.4 BIODURO 366 13.2.5 SYNBIO TECHNOLOGIES 367 13.2.6 ABSOLUTE ANTIBODY 368 13.2.7 ADIMAB 369 13.2.8 ISOGENICA 370 13.2.9 ABLEXIS 371 13.2.10 FAIRJOURNEY 372 14 APPENDIX 373 14.1 DISCUSSION GUIDE 373 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 376 14.3 CUSTOMIZATION OPTIONS 378 14.4 RELATED REPORTS 378 14.5 AUTHOR DETAILS 379

TABLE 1 ANTIBODY DISCOVERY SERVICES MARKET: INCLUSIONS & EXCLUSIONS 37 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS IN ANTIBODY DISCOVERY SERVICES MARKET 48 TABLE 3 ANTIBODY DISCOVERY SERVICES MARKET: RISK ANALYSIS 51 TABLE 4 KEY IP/PLATFORM ASSETS OF KEY PLAYERS, 2022–2025 70 TABLE 5 IMPACT ANALYSIS OF ANTIBODY DISCOVERY SERVICES MARKET DYNAMICS 72 TABLE 6 MAJOR VENTURE AND PARTNERSHIP FUNDING FOR BIOLOGICS, 2025 73 TABLE 7 ROLE OF RAW MATERIAL SUPPLIERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM 80 TABLE 8 ROLE OF ANTIBODY DISCOVERY SERVICE PROVIDERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM 80 TABLE 9 ROLE OF END USERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM 81 TABLE 10 ROLE OF REGULATORY BODIES IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM 81 TABLE 11 NUMBER OF PATENTS FILED (APPLIED/GRANTED) IN ANTIBODY DISCOVERY SERVICES MARKET, 2014−2024 86 TABLE 12 LIST OF KEY PATENTS IN ANTIBODY DISCOVERY SERVICES MARKET 88 TABLE 13 LIST OF KEY CONFERENCES & EVENTS IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2025–DECEMBER 2026 89 TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 TABLE 18 ANTIBODY DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES 94 TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%), BY TYPE 97 TABLE 20 KEY BUYING CRITERIA FOR MAJOR END USERS 98 TABLE 21 KEY PLAYERS IMPLEMENTING AI IN ANTIBODY DISCOVERY SERVICES 100 TABLE 22 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 102 TABLE 23 TARGET IDENTIFICATION & VALIDATION MARKET, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 24 NORTH AMERICA: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 25 EUROPE: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 26 ASIA PACIFIC: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 27 LATIN AMERICA: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 28 MIDDLE EAST: TARGET IDENTIFICATION & VALIDATION MARKET, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 29 GCC COUNTRIES: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 30 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 31 NORTH AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 32 EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 33 ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 34 LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 35 MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 36 GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 37 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 110 TABLE 38 PHAGE DISPLAY TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 39 NORTH AMERICA: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 40 EUROPE: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 41 ASIA PACIFIC: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 42 LATIN AMERICA: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 43 MIDDLE EAST: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 44 GCC COUNTRIES: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 45 HYBRIDOMA TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 46 NORTH AMERICA: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 47 EUROPE: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 48 ASIA PACIFIC: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 49 LATIN AMERICA: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 50 MIDDLE EAST: HYBRIDOMA TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 51 GCC COUNTRIES: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 52 SINGLE-CELL TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 53 NORTH AMERICA: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 54 EUROPE: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 55 ASIA PACIFIC: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 56 LATIN AMERICA: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 57 MIDDLE EAST: SINGLE-CELL TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 58 GCC COUNTRIES: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 59 OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 60 NORTH AMERICA: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 61 EUROPE: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 62 ASIA PACIFIC: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 63 LATIN AMERICA: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 64 MIDDLE EAST: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 65 GCC COUNTRIES: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 66 ANTIGEN DESIGN & PRODUCTION MARKET, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 67 NORTH AMERICA: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 68 EUROPE: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 69 ASIA PACIFIC: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 70 LATIN AMERICA: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 71 MIDDLE EAST: ANTIGEN DESIGN & PRODUCTION MARKET, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 72 GCC COUNTRIES: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 73 IMMUNIZATION & HOST MANAGEMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 74 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 75 EUROPE: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 76 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 77 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 78 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 79 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 80 OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 81 NORTH AMERICA: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 82 EUROPE: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 83 ASIA PACIFIC: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 84 LATIN AMERICA: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 85 MIDDLE EAST: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 86 GCC COUNTRIES: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 87 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 137 TABLE 88 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 89 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 90 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 91 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 92 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 93 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 94 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 95 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 96 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 97 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 98 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 99 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 100 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 101 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 102 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 103 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 104 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 105 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 106 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 107 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 108 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 109 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 110 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 111 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 112 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 113 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 114 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 115 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 116 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 117 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 118 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 119 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 120 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 121 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 122 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 123 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 156 TABLE 124 ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 125 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 126 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 127 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 128 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 129 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 130 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 131 ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 132 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 133 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 134 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 135 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 136 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 137 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 138 ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 139 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 140 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 141 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 142 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 143 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 144 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 145 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 168 TABLE 146 ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 147 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 148 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 149 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 150 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 151 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 152 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 153 ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 154 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 155 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 156 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 157 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 158 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 159 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 160 ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 161 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 162 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 163 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 164 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 165 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 166 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 167 ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 180 TABLE 168 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 169 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 182 TABLE 170 NORTH AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 183 TABLE 171 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 183 TABLE 172 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 184 TABLE 173 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 184 TABLE 174 NORTH AMERICA: KEY MACROINDICATORS 185 TABLE 175 US: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 176 US: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 186 TABLE 177 US: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 187 TABLE 178 US: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 187 TABLE 179 US: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 188 TABLE 180 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 181 CANADA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 189 TABLE 182 CANADA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 190 TABLE 183 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 190 TABLE 184 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 191 TABLE 185 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 186 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 187 EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 192 TABLE 188 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 193 TABLE 189 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 193 TABLE 190 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 194 TABLE 191 EUROPE: KEY MACROINDICATORS 195 TABLE 192 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 193 GERMANY: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 196 TABLE 194 GERMANY: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 197 TABLE 195 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 197 TABLE 196 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 198 TABLE 197 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 198 UK: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 199 TABLE 199 UK: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 200 TABLE 200 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 200 TABLE 201 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 201 TABLE 202 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 202 TABLE 203 FRANCE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 202 TABLE 204 FRANCE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 203 TABLE 205 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 203 TABLE 206 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 204 TABLE 207 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 208 ITALY: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 205 TABLE 209 ITALY: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 206 TABLE 210 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 206 TABLE 211 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 207 TABLE 212 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 213 SPAIN: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 208 TABLE 214 SPAIN: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 209 TABLE 215 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 209 TABLE 216 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 210 TABLE 217 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 210 TABLE 218 REST OF EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 211 TABLE 219 REST OF EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 211 TABLE 220 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 212 TABLE 221 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 212 TABLE 222 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 223 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 224 ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 215 TABLE 225 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 215 TABLE 226 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 216 TABLE 227 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 216 TABLE 228 ASIA PACIFIC: KEY MACROINDICATORS 217 TABLE 229 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 218 TABLE 230 CHINA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 218 TABLE 231 CHINA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 219 TABLE 232 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 219 TABLE 233 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 220 TABLE 234 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 235 JAPAN: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 221 TABLE 236 JAPAN: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 222 TABLE 237 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 222 TABLE 238 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 223 TABLE 239 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 240 INDIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 224 TABLE 241 INDIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 225 TABLE 242 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 225 TABLE 243 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 226 TABLE 244 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 227 TABLE 245 SOUTH KOREA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 227 TABLE 246 SOUTH KOREA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 228 TABLE 247 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 228 TABLE 248 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 229 TABLE 249 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 230 TABLE 250 AUSTRALIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 230 TABLE 251 AUSTRALIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 231 TABLE 252 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 231 TABLE 253 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 232 TABLE 254 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 255 REST OF ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 233 TABLE 256 REST OF ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 234 TABLE 257 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 234 TABLE 258 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 235 TABLE 259 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 235 TABLE 260 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 261 LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 236 TABLE 262 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 237 TABLE 263 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 237 TABLE 264 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 265 LATIN AMERICA: KEY MACROINDICATORS 238 TABLE 266 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 267 BRAZIL: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 240 TABLE 268 BRAZIL: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 240 TABLE 269 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 241 TABLE 270 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 241 TABLE 271 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 272 MEXICO: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 242 TABLE 273 MEXICO: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 243 TABLE 274 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 243 TABLE 275 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 276 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 277 REST OF LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 245 TABLE 278 REST OF LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 246 TABLE 279 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 246 TABLE 280 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 281 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 247 TABLE 282 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 283 MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 248 TABLE 284 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 249 TABLE 285 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 249 TABLE 286 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 250 TABLE 287 MIDDLE EAST: KEY MACROINDICATORS 250 TABLE 288 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 251 TABLE 289 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 290 GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 252 TABLE 291 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 252 TABLE 292 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 253 TABLE 293 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 253 TABLE 294 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 295 UAE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 254 TABLE 296 UAE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 255 TABLE 297 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 255 TABLE 298 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 256 TABLE 299 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 300 KINGDOM OF SAUDI ARABIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 257 TABLE 301 KINGDOM OF SAUDI ARABIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 258 TABLE 302 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 258 TABLE 303 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 259 TABLE 304 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 305 REST OF GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 260 TABLE 306 REST OF GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 261 TABLE 307 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 261 TABLE 308 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 262 TABLE 309 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 310 REST OF MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 263 TABLE 311 REST OF MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 264 TABLE 312 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 264 TABLE 313 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 265 TABLE 314 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 315 AFRICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 266 TABLE 316 AFRICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION) 267 TABLE 317 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 267 TABLE 318 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 268 TABLE 319 AFRICA: KEY MACROINDICATORS 268 TABLE 320 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2022–AUGUST 2025 269 TABLE 321 ANTIBODY DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION 274 TABLE 322 ANTIBODY DISCOVERY SERVICES MARKET: REGION FOOTPRINT 278 TABLE 323 ANTIBODY DISCOVERY SERVICES MARKET: TYPE FOOTPRINT 279 TABLE 324 ANTIBODY DISCOVERY SERVICES MARKET: HOST FOOTPRINT 280 TABLE 325 ANTIBODY DISCOVERY SERVICES MARKET: MOLECULE FOOTPRINT 281 TABLE 326 ANTIBODY DISCOVERY SERVICES MARKET: LIST OF KEY STARTUPS/SME PLAYERS 284 TABLE 327 ANTIBODY DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY TYPE AND REGION 285 TABLE 328 ANTIBODY DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025 288 TABLE 329 ANTIBODY DISCOVERY SERVICES MARKET: DEALS, JANUARY 2022–AUGUST 2025 288 TABLE 330 ANTIBODY DISCOVERY SERVICES MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025 289 TABLE 331 WUXI BIOLOGICS: COMPANY OVERVIEW 291 TABLE 332 WUXI BIOLOGICS: SERVICES OFFERED 292 TABLE 333 WUXI BIOLOGICS: DEALS, JANUARY 2022–AUGUST 2025 293 TABLE 334 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022–AUGUST 2025 294 TABLE 335 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 295 TABLE 336 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 296 TABLE 337 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–AUGUST 2025 297 TABLE 338 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025 298 TABLE 339 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 300 TABLE 340 CHARLES RIVER LABORATORIES: SERVICES OFFERED 301 TABLE 341 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–AUGUST 2025 302 TABLE 342 EVOTEC: COMPANY OVERVIEW 304 TABLE 343 EVOTEC: SERVICES OFFERED 305 TABLE 344 EVOTEC: DEALS, JANUARY 2022–AUGUST 2025 306 TABLE 345 EVOTEC: CONTRACTS, JANUARY 2022–AUGUST 2025 307 TABLE 346 EVOTEC: EXPANSIONS, JANUARY 2022–AUGUST 2025 307 TABLE 347 EVOTEC: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 308 TABLE 348 BIOCYTOGEN: COMPANY OVERVIEW 309 TABLE 349 BIOCYTOGEN: SERVICES OFFERED 310 TABLE 350 BIOCYTOGEN: SERVICE LAUNCHES, JANUARY 2022−AUGUST 2025 311 TABLE 351 BIOCYTOGEN: DEALS, JANUARY 2022–AUGUST 2025 311 TABLE 352 BIOCYTOGEN: EXPANSIONS, JANUARY 2022–AUGUST 2025 313 TABLE 353 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 315 TABLE 354 EUROFINS SCIENTIFIC: SERVICES OFFERED 316 TABLE 355 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022–AUGUST 2025 317 TABLE 356 SHANGHAI CHEMPARTNER: COMPANY OVERVIEW 318 TABLE 357 SHANGHAI CHEMPARTNER: SERVICES OFFERED 318 TABLE 358 SHANGHAI CHEMPARTNER: DEALS, JANUARY 2022–AUGUST 2025 319 TABLE 359 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): COMPANY OVERVIEW 320 TABLE 360 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): SERVICES OFFERED 322 TABLE 361 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): EXPANSIONS, JANUARY 2022–AUGUST 2025 323 TABLE 362 SINO BIOLOGICAL, INC.: COMPANY OVERVIEW 324 TABLE 363 SINO BIOLOGICAL, INC.: SERVICES OFFERED 325 TABLE 364 SINO BIOLOGICAL, INC.: DEALS, JANUARY 2022–AUGUST 2025 326 TABLE 365 SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025 327 TABLE 366 SAMSUNG BIOLOGICS: COMPANY OVERVIEW 328 TABLE 367 SAMSUNG BIOLOGICS: SERVICES OFFERED 329 TABLE 368 SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025 330 TABLE 369 GENSCRIPT: COMPANY OVERVIEW 331 TABLE 370 GENSCRIPT: SERVICES OFFERED 332 TABLE 371 GENSCRIPT: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025 333 TABLE 372 GENSCRIPT: DEALS, JANUARY 2022–AUGUST 2025 334 TABLE 373 CURIA GLOBAL, INC.: COMPANY OVERVIEW 335 TABLE 374 CURIA GLOBAL, INC.: SERVICES OFFERED 335 TABLE 375 CURIA GLOBAL, INC.: DEALS, JANUARY 2022–AUGUST 2025 336 TABLE 376 CURIA GLOBAL, INC.: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 337 TABLE 377 TWIST BIOSCIENCE: COMPANY OVERVIEW 338 TABLE 378 TWIST BIOSCIENCE: SERVICES OFFERED 339 TABLE 379 TWIST BIOSCIENCE: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025 341 TABLE 380 TWIST BIOSCIENCE: DEALS, JANUARY 2022−AUGUST 2025 341 TABLE 381 TWIST BIOSCIENCE: EXPANSIONS, JANUARY 2022–AUGUST 2025 341 TABLE 382 HARBOUR BIOMED: COMPANY OVERVIEW 342 TABLE 383 HARBOUR BIOMED: SERVICES OFFERED 343 TABLE 384 HARBOUR BIOMED: DEALS, JANUARY 2022−AUGUST 2025 343 TABLE 385 HARBOUR BIOMED: OTHER DEVELOPMENTS, JANUARY 2022−AUGUST 2025 345 TABLE 386 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW 346 TABLE 387 ARAGEN LIFE SCIENCES LTD.: SERVICES OFFERED 347 TABLE 388 ARAGEN LIFE SCIENCES LTD.: EXPANSIONS, JANUARY 2022–AUGUST 2025 347 TABLE 389 DANAHER CORPORATION: COMPANY OVERVIEW 348 TABLE 390 DANAHER CORPORATION: SERVICES OFFERED 349 TABLE 391 DANAHER CORPORATION: DEALS, JANUARY 2022–AUGUST 2025 350 TABLE 392 CREATIVE BIOLABS: COMPANY OVERVIEW 351 TABLE 393 CREATIVE BIOLABS: SERVICES OFFERED 351 TABLE 394 VIVA BIOTECH: COMPANY OVERVIEW 353 TABLE 395 VIVA BIOTECH: SERVICES OFFERED 355 TABLE 396 IMMUNOPRECISE ANTIBODIES LTD.: COMPANY OVERVIEW 356 TABLE 397 IMMUNOPRECISE ANTIBODIES LTD.: SERVICES OFFERED 357 TABLE 398 IMMUNOPRECISE ANTIBODIES LTD.: DEALS, JANUARY 2022−AUGUST 2025 359 TABLE 399 FUSION ANTIBODIES: COMPANY OVERVIEW 360 TABLE 400 FUSION ANTIBODIES: SERVICES OFFERED 361 TABLE 401 ABZENA: COMPANY OVERVIEW 363 TABLE 402 ALLOY THERAPEUTICS, INC.: COMPANY OVERVIEW 364 TABLE 403 INTEGRAL MOLECULAR: COMPANY OVERVIEW 365 TABLE 404 BIODURO: COMPANY OVERVIEW 366 TABLE 405 SYNBIO TECHNOLOGIES: COMPANY OVERVIEW 367 TABLE 406 ABSOLUTE ANTIBODY: COMPANY OVERVIEW 368 TABLE 407 ADIMAB: COMPANY OVERVIEW 369 TABLE 408 ISOGENICA: COMPANY OVERVIEW 370 TABLE 409 ABLEXIS: COMPANY OVERVIEW 371 TABLE 410 FAIRJOURNEY: COMPANY OVERVIEW 372 FIGURE 1 ANTIBODY DISCOVERY SERVICES MARKET SEGMENTATION & REGIONAL SCOPE 36 FIGURE 2 ANTIBODY DISCOVERY SERVICES MARKET: YEARS CONSIDERED 37 FIGURE 3 ANTIBODY DISCOVERY SERVICES MARKET: RESEARCH DESIGN 39 FIGURE 4 ANTIBODY DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 41 FIGURE 5 ANTIBODY DISCOVERY SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 42 FIGURE 6 COMPANY REVENUE ANALYSIS-BASED MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 43 FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC (US), 2024 44 FIGURE 8 ANTIBODY DISCOVERY SERVICES MARKET SIZE VALIDATION FROM PRIMARY EXPERTS 45 FIGURE 9 ANTIBODY DISCOVERY SERVICES MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 45 FIGURE 10 ANTIBODY DISCOVERY SERVICES MARKET: CAGR PROJECTIONS 47 FIGURE 11 ANTIBODY DISCOVERY SERVICES MARKET: DATA TRIANGULATION METHODOLOGY 49 FIGURE 12 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 53 FIGURE 13 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 53 FIGURE 14 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2025 VS. 2030 (USD MILLION) 54 FIGURE 15 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION) 55 FIGURE 16 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 55 FIGURE 17 ANTIBODY DISCOVERY SERVICES MARKET: REGIONAL SNAPSHOT 56 FIGURE 18 SNAPSHOT: GLOBAL ANTIBODY DISCOVERY SERVICES MARKET SIZE, GROWTH RATE, AND FORECAST (USD MILLION) 60 FIGURE 19 INCREASING VENTURE FUNDING AND INVESTMENTS TO DRIVE MARKET 61 FIGURE 20 US AND MONOCLONAL ANTIBODIES COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024 62 FIGURE 21 MONOCLONAL ANTIBODIES TO ACCOUNT FOR LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD 63 FIGURE 22 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 63 FIGURE 23 ANTIBODY ENGINEERING & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 64 FIGURE 24 ANTIBODY DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 71 FIGURE 25 ANTIBODY DISCOVERY SERVICES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 77 FIGURE 26 ANTIBODY DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS 78 FIGURE 27 ANTIBODY DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS 79 FIGURE 28 NIH FUNDING FOR ANTIBODY DISCOVERY, 2014–2025 (USD MILLION) 83 FIGURE 29 TOP PATENT APPLICANTS/OWNERS AND NUMBER OF PATENTS GRANTED IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2014–DECEMBER 2024 87 FIGURE 30 ANTIBODY DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 95 FIGURE 31 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE 97 FIGURE 32 KEY BUYING CRITERIA FOR MAJOR END USERS 98 FIGURE 33 IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET 100 FIGURE 34 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET SNAPSHOT 181 FIGURE 35 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET SNAPSHOT 213 FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET, 2020–2024 (USD MILLION) 272 FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET (2024) 274 FIGURE 38 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 276 FIGURE 39 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT 277 FIGURE 40 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 283 FIGURE 41 EV/EBITDA OF KEY PLAYERS 286 FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS 286 FIGURE 43 ANTIBODY DISCOVERY SERVICES MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS 287 FIGURE 44 WUXI BIOLOGICS: COMPANY SNAPSHOT 292 FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 296 FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 301 FIGURE 47 EVOTEC: COMPANY SNAPSHOT 305 FIGURE 48 BIOCYTOGEN: COMPANY SNAPSHOT 310 FIGURE 49 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 316 FIGURE 50 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): COMPANY SNAPSHOT 321 FIGURE 51 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT 325 FIGURE 52 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT 329 FIGURE 53 GENSCRIPT: COMPANY SNAPSHOT 332 FIGURE 54 TWIST BIOSCIENCE: COMPANY SNAPSHOT 339 FIGURE 55 HARBOUR BIOMED: COMPANY SNAPSHOT 342 FIGURE 56 ARAGEN LIFE SCIENCES LTD.: COMPANY SNAPSHOT 346 FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT 349 FIGURE 58 VIVA BIOTECH: COMPANY SNAPSHOT 354 FIGURE 59 IMMUNOPRECISE ANTIBODIES LTD.: COMPANY SNAPSHOT 357 FIGURE 60 FUSION ANTIBODIES: COMPANY SNAPSHOT 361